Prediction: My Top 2 Stocks to Buy Now Will Outperform the Stock Market Over the Next Decade

The article highlights Amazon and Eli Lilly as long-term stock picks, citing AWS sales growth of 37% in Q2, nearly 40% operating margins, and CEO Andy Jassy’s view that AWS could reach $600 billion in annual sales by 2036; Amazon plans to spend $220 billion in 2026 on capacity and infrastructure. Eli Lilly’s Q2 Mounjaro and Zepbound sales rose 91% to $9.9 billion and 44% to $4.9 billion, respectively, while its Foundayo pill adds another GLP-1 option. Morgan Stanley projects global GLP-1 sales of $190 billion by 2035, and Wall Street expects Lilly annualized earnings growth of roughly 22% over the next five years.

Analysis

The central risk in both stories is not demand but the conversion of demand into durable, incremental cash earnings. For Amazon, AI capacity spending can support AWS growth while simultaneously raising depreciation and risking underutilized infrastructure if customer workloads or monetization lag. The key read-through is not headline cloud growth alone: track AWS operating income, capex, depreciation, and capacity utilization. Microsoft and Google are the relevant competitive checks; aggressive capacity buildout across providers could pressure returns even if the market expands.

For Eli Lilly, the upside case depends on sustained access and net economics, not just patient interest. Oral uptake could broaden the addressable pool, but verify regulatory status, real-world persistence, supply, payer coverage, and realized pricing. Novo Nordisk is the most direct competitive benchmark; reimbursement expansion may increase volume while also strengthening payer leverage.

Near term (days), this article adds little beyond an already bullish narrative; without valuation and positioning data, chasing either name is not justified. Over 1–3 months, earnings disclosures on AWS returns and Lilly’s launch/access metrics are the relevant catalysts. Over 6–18 months, Amazon’s capital productivity and Lilly’s competitive, reimbursement, and supply durability matter most. The contrarian point: strong secular demand does not guarantee attractive shareholder returns if investment intensity or pricing absorbs the gains.

Key Decisions for Investors

• AMZN: Prefer staged exposure on weakness rather than buying a narrative-driven extension. Reassess after results using AWS operating-income growth versus capex and depreciation; weaken the thesis if spending accelerates while cloud profitability or utilization deteriorates.
• LLY: Hold or add only where valuation leaves room for execution risk; do not treat projected category growth as company-specific earnings. Track oral-product uptake, supply, payer access, and realized net pricing; reassess if access expands without durable volume or if pricing/reimbursement erodes economics.
• Avoid initiating a forced pair trade from this article alone. Compare LLY’s launch and access metrics with Novo Nordisk’s before expressing relative value; compare Amazon’s cloud returns with Microsoft and Google before overweighting AI infrastructure.
• Treat coverage, launch, and management outlook claims as verification items. A material guidance reduction, weak AWS returns on invested capital, or evidence of Lilly access/pricing friction would falsify the respective bullish thesis.